Efficient infection of a human B cell line with cell-free Kaposi's sarcoma-associated herpesvirus

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1748-1757

  Dollery, Stephen J ^a   Santiago Crespo, Rey J ^a   Kardava, Lela ^a   Moir, Susan ^a   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; LATENCY ASSOCIATED NUCLEAR ANTIGEN; PUROMYCIN; RED FLUORESCENT PROTEIN;

ARTICLE; B CELL CULTURE; B CELL LYMPHOMA; CELL FREE SYSTEM; CELL LYSATE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; INFECTION SENSITIVITY; LATENT VIRUS INFECTION; MC116 CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS STRAIN;

B-LYMPHOCYTES; CELL LINE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; MODELS, BIOLOGICAL; VIRAL PROTEINS; VIRUS LATENCY;

EID: 84892463414     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03063-13     Document Type: Article

References (69)

1. Wen KW, Damania B. 2010. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett. 289:140-150. http://dx.doi.org/10.1016/j.canlet.2009.07.004.
2. Cesarman E. 2011. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 305:163-174. http://dx.doi.org/10.1016/j.canlet.2011.03.003.
3. Gantt S, Casper C. 2011. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr. Opin. Infect. Dis. 24:295-301. http://dx.doi.org/10.1097/QCO.0b013e3283486d04.
4. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA-sequences in AIDS-associated Kaposi's-sarcoma. Science 266:1865-1869. http://dx.doi .org/10.1126/science.7997879.
5. Mesri EA, Cesarman E, Boshoff C. 2010. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10:707-719. http://dx.doi.org/10 .1038/nrc2888.
6. Ganem D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Invest. 120:939-949. http://dx .doi.org/10.1172/JCI40567.
7. Uldrick TS, Whitby D. 2011. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett. 305:150-162. http://dx.doi.org/10.1016/j.canlet.2011.02.006.
8. Reddy D, Mitsuyasu R. 2011. HIV-associated multicentric Castleman disease. Curr. Opin. Oncol. 23:475-481. http://dx.doi.org/10.1097/CCO .0b013e328349c233.
9. Uldrick TS, Polizzotto MN, Yarchoan R. 2012. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr. Opin. Oncol. 24:495-505. http://dx.doi.org/10.1097/CCO.0b013e 328355e0f3.
10. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C. 1999. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. U.S.A. 96:4546-4551. http://dx.doi.org/10 .1073/pnas.96.8.4546.
11. Whitby D, Howard MR, Tenantflowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FEA, Aldam DM, Denton AS, Miller RF, Weller IVD, Weiss RA, Tedder RS, Schulz TF. 1995. Detections of Kaposi-sarcoma associated herpesvirus in peripheral-blood of HIVinfected individuals and progression to Kaposi's-sarcoma. Lancet 346: 799-802. http://dx.doi.org/10.1016/S0140-6736(95)91619-9.
12. Ambroziak JA, Blackbourn DJ, Herndier BG, Glogau RG, Gullett JH, McDonald AR, Lennette ET, Levy JA. 1995. Herpes-like sequences in HIV-infected and uninfected Kaposi's-sarcoma patients. Science 268: 582-583. http://dx.doi.org/10.1126/science.7725108.
13. Huang YQ, Li JJ, Poiesz BJ, Kaplan MH, FriedmanKien AE. 1997. Detection of the herpesvirus-like DNA sequences in matched specimens of semen and blood from patients with AIDS-related Kaposi's sarcoma by polymerase chain reaction in situ hybridization. Am. J. Pathol. 150:147-153.
14. Carbone A, Cesarman E, Gloghini A, Drexler HG. 2010. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS 24:479-490. http://dx.doi.org/10.1097/QAD.0b013e3283365395.
15. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MAS, Posnett DN, Knowles DM, Asch AS. 1996. Human herpesvirus-8/Kaposi's sarcomaassociated herpesvirus is a new transmissible virus that infects B cells. J. Exp. Med. 183:2385-2390. http://dx.doi.org/10.1084/jem.183.5.2385.
16. Renne R, Zhong WD, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342-346. http://dx.doi.org/10.1038/nm0396-342.
17. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U.S.A. 93:14862-14867. http://dx.doi.org/10.1073/pnas .93.25.14862.
18. Rappocciolo G, Hensler HR, Jais M, Reinhart TA, Pegu A, Jenkins FJ, Rinaldo CR. 2008. Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J. Virol. 82:4793-4806. http://dx.doi.org/10.1128/JVI.01587-07.
19. Hassman LM, Ellison TJ, Kedes DH. 2011. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J. Clin. Invest. 121:752-768. http://dx.doi.org/10.1172/JCI44185.
20. Myoung J, Ganem D. 2011. Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4(+) T cells. J. Clin. Invest. 121:1130-1140. http://dx.doi.org/10.1172/JCI43755.
21. Myoung JJ, Ganem D. 2011. Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology 413:1-11. http://dx.doi.org/10.1016/j.virol.2010.12.036.
22. Vieira J, Huang ML, Koelle DM, Corey L. 1997. Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with history of Kaposi's sarcoma. J. Virol. 71:7083-7087.
23. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. 1997. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virusinfected men: clinical and immunologic correlates. J. Infect. Dis. 176:94-102. http://dx.doi.org/10.1086/514045.
24. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, Celum C, Selke S, Corey L. 2000. Mucosal shedding of human herpesvirus 8 in men. N. Engl. J. Med. 343:1369-1377. http://dx.doi.org/10.1056/NEJM200011093431904.
25. Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, Page T, Casabonne D, Gilks CF, Cassol SA, Whitby D, Schulz TF. 2004. Mother-to-child transmission of human herpesvirus-8 in South Africa. J. Infect. Dis. 190:1068-1075. http://dx.doi.org/10.1086/423326.
26. Casper C, Krantz E, Selke S, Kuntz SR, Wang J, Huang ML, Pauk JS, Corey L, Wald A. 2007. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J. Infect. Dis. 195:30-36. http://dx.doi.org/10.1086/509621.
27. Bagni R, Whitby D. 2009. Kaposi's sarcoma-associated herpesvirus transmission and primary infection. Curr. Opin. HIV AIDS 4:22-26. http://dx .doi.org/10.1097/COH.0b013e32831add5a.
28. Speck SH, Ganem D. 2010. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 8:100-115. http://dx.doi .org/10.1016/j.chom.2010.06.014.
29. Zhou FC, Zhang YJ, Deng JH, Wang XP, Pan HY, Hettler E, Gao SJ. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J. Virol. 76:6185-6196. http://dx.doi.org/10.1128/JVI.76 .12.6185-6196.2002.
30. Bechtel JT, Liang YY, Hvidding J, Ganem D. 2003. Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J. Virol. 77: 6474-6481. http://dx.doi.org/10.1128/JVI.77.11.6474-6481.2003.
31. Vieira J, O'Hearn PM. 2004. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 325:225-240. http://dx.doi.org/10.1016/j.virol.2004.03.049.
32. Renne R, Blackbourn D, Whitby D, Levy J, Ganem D. 1998. Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J. Virol. 72:5182-5188.
33. Blackbourn DJ, Lennette E, Klencke B, Moses A, Chandran B, Weinstein M, Glogau RG, Witte MH, Way DL, Kutzkey T, Herndier B, Levy JA. 2000. The restricted cellular host range of human herpesvirus 8. AIDS 14:1123-1133. http://dx.doi.org/10.1097/00002030-200006160-00009.
34. Friborg J, Kong WP, Flowers CC, Flowers SL, Sun YN, Foreman KE, Nickoloff BJ, Nabel GJ. 1998. Distinct biology of Kaposi's sarcomaassociated herpesvirus from primary lesions and body cavity lymphomas. J. Virol. 72:10073-10082.
35. Myoung J, Ganem D. 2011. Infection of lymphoblastoid cell lines by Kaposi's sarcoma-associated herpesvirus: critical role of cell-associated virus. J. Virol. 85:9767-9777. http://dx.doi.org/10.1128/JVI.05136-11.
36. Myoung J, Ganem D. 2011. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 174:12-21. http://dx.doi.org/10.1016/j.jviromet.2011.03.012.
37. Hahn A, Birkmann A, Wies E, Dorer D, Mahr K, Sturzl M, Titgemeyer F, Neipel F. 2009. Kaposi's sarcoma-associated herpesvirus gH/gL: glycoprotein export and interaction with cellular receptors. J. Virol. 83:396-407. http://dx.doi.org/10.1128/JVI.01170-08.
38. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. 2005. Inhibiting primary effusion lymphoma, by lentiviral vectors encoding short hairpin RNA. Blood 105:2510-2518. http://dx.doi.org/10 .1182/blood-2004-08-3052.
39. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C. 2000. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412.
40. Du MQ, Liu HX, Diss TC, Ye HT, Hamoudi RA, Dupin N, Meignin V, Oksenhendler E, Boshoff C, Isaacson PG. 2001. Kaposi sarcomaassociated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-2136. http://dx.doi.org/10.1182/blood.V97 .7.2130.
41. Magrath IT, Pizzo PA, Whangpeng J, Douglass EC, Alabaster O, Gerber P, Freeman CB, Novikovs L. 1980. Characterization of lymphomaderived cell-lines-comparison of cell-lines positive and negative for Epstein-Barr virus nuclear antigen. 1. Physical, cytogenetic, and growth characteristics. J. Natl. Cancer Inst. 64:465-476.
42. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS. 1978. Biology of human malignant-lymphomas. 4. Functional characterization of 10 diffuse histiocytic lymphoma cell lines. Cancer 42:2379-2391.
43. Park LS, Friend D, Price V, Anderson D, Singer J, Prickett KS, Urdal DL. 1989. Heterogeneity in human interleukin-3 receptors-a subclass that binds human granulocyte macrophage colony stimulating factor. J. Biol. Chem. 264:5420-5427.
44. Greaves M, Janossy G. 1978. Patterns of gene expression and cellular origins of human leukemias. Biochim. Biophys. Acta 516:193-230.
45. Goy A, Ramdas L, Remache YK, Gu J, Fayad L, Hayes KJ, Coombes KR, Barkoh BA, Katz R, Ford R, Cabanillas F, Gilles F. 2003. Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations. Lab. Invest. 83:913-916. http://dx.doi.org/10 .1097/01.LAB.0000074890.89650.AD.
46. Spira G, Aman P, Koide N, Lundin G, Klein G, Hall K. 1981. Cellsurface immunoglobulin and insulin-receptor expression in an EBVnegative lymphoma cell-line and its EBV-converted sublines. J. Immunol. 126:122-126.
47. Singer PA, Williamson AR. 1980. Cell-surface immunoglobulin muchains and gamma-chains of human lymphoid-cells are of higher apparent molecular-weight than their secreted counterparts. Eur. J. Immunol. 10:180-186. http://dx.doi.org/10.1002/eji.1830100305.
48. Winter JN, Variakojis D, Epstein AL. 1984. Phenotypic analysis of established diffuse histiocytic lymphoma cell-lines utilizing monoclonalantibodies and cytochemical techniques. Blood 63:140-146.
49. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. 2005. Identification and characterization of circulating human transitional B cells. Blood 105:4390-4398. http://dx.doi.org/10.1182/blood-2004-11-4284.
50. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. 2001. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167:3610-3618.
51. Sturzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. 2013. Kaposi's sarcoma-derived cell line SLK is not of endothelial origin, but is a contam-inant from a known renal carcinoma cell line. Int. J. Cancer 132:1954-1958. http://dx.doi.org/10.1002/ijc.27849.
52. Adang LA, Parsons CH, Kedes DH. 2006. Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by high-throughput single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection. J. Virol. 80:10073-10082. http://dx.doi.org/10.1128/JVI.01156-06.
53. Miller G, Rigsby MO, Heston L, Grogan E, Sun R, Metroka C, Levy JA, Gao SJ, Chang Y, Moore PS. 1996. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N. Engl. J. Med. 334:1292-1297.
54. Shaw RN, Arbiser JL, Offermann MK. 2000. Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 14:899-902. http://dx.doi.org/10.1097/00002030-200005050-00021.
55. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, Lenoir GM. 1987. Epstein-Barr-virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064.
56. Forrest JC, Speck SH. 2008. Establishment of B-cell lines latently infected with reactivation-competent murine gammaherpesvirus 68 provides evidence for viral alteration of a DNA damage-signaling cascade. J. Virol. 82:7688-7699. http://dx.doi.org/10.1128/JVI.02689-07.
57. Bilello JP, Lang SM, Wang F, Aster JC, Desrosiers RC. 2006. Infection and persistence of rhesus monkey rhadinovirus in immortalized B-cell lines. J. Virol. 80:3644-3649. http://dx.doi.org/10.1128/JVI.80.7.3644-3649.2006.
58. Hahn HS, Desrosiers RC. 2013. Rhesus monkey rhadinovirus uses Eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog. 9:e1003360. http://dx.doi.org/10.1371/journal.ppat .1003360.
59. Coleman CB, Nealy MS, Tibbetts SA. 2010. Immature and transitional B cells are latency reservoirs for a gammaherpesvirus. J. Virol. 84:13045-13052. http://dx.doi.org/10.1128/JVI.01455-10.
60. Takada K. 1984. Cross-linking of cell-surface immunoglobulins induces Epstein-Barr virus in Burkitt-lymphoma lines. Int. J. Cancer 33:27-32.
61. Tovey MG, Lenoir G, Begonlours J. 1978. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276:270-272.
62. Moser JM, Upton JW, Gray KS, Speck SH. 2005. Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency. J. Virol. 79:5227-5231. http://dx.doi.org/10.1128/JVI.79.8 .5227-5231.2005.
63. Damania B, Desrosiers RC. 2001. Simian homologues of human herpesvirus 8. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:535-543. http://dx.doi .org/10.1098/rstb.2000.0782.
64. Barton E, Mandal P, Speck SH. 2011. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu. Rev. Immunol. 29: 351-397. http://dx.doi.org/10.1146/annurev-immunol-072710-081639.
65. Kalla M, Hammerschmidt W. 2012. Human B cells on their route to latent infection-early but transient expression of lytic genes of Epstein-Barr virus. Eur. J. Cell Biol. 91:65-69. http://dx.doi.org/10.1016/j.ejcb .2011.01.014.
66. Kati S, Tsao EH, Gunther T, Weidner-Glunde M, Rothamel T, Grundhoff A, Kellam P, Schulz TF. 2013. Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells. J. Virol. 87:8004-8016. http://dx.doi.org/10.1128/JVI .00506-13.
67. Zhu L, Puri V, Chandran B. 1999. Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies. Virology 262: 237-249. http://dx.doi.org/10.1006/viro.1999.9900.
68. Chatterjee D, Chandran B, Berger EA. 2012. Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein. MAbs 4:233-242. http://dx.doi.org/10.4161/mabs.4.2.19262.
69. Cai Y, Berger EA. 2011. An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection. Antiviral Res. 90:143-150. http://dx.doi.org/10.1016/j.antiviral.2011.03.175.